Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  04:00 2022-09-28 pm EDT
63.93 USD   +2.08%
01:04pGilead Sciences : WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
AQ
09/22Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
BU
09/20Merck & Co. to Evaluate Lower Dose of Once-daily HIV-1 Pill in Late-stage Clinical Program
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

UBS Adjusts Gilead Sciences Price Target to $65 From $63, Maintains Neutral Rating

08/04/2022 | 11:16am EDT


© MT Newswires 2022
All news about GILEAD SCIENCES, INC.
01:04pGilead Sciences : WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Se..
AQ
09/22Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral..
BU
09/20Merck & Co. to Evaluate Lower Dose of Once-daily HIV-1 Pill in Late-stage Clinical Prog..
MT
09/20Gilead Sciences Completes Acquisition of MiroBio for $405 Million
MT
09/20Gilead Sciences Completes Acquisition of MiroBio
BU
09/20Merck to start studying lower dose of HIV drug after FDA hold
RE
09/20Merck to Begin New Phase 3 Trial for Islatravir HIV-1 Treatment
DJ
09/20Gilead Sciences, Inc. completed the acquisition of MiroBio Ltd.
CI
09/18Everest Medicines Names CEO
MT
09/16Gilead Sciences, Inc. - WHO Expands Recommendation for Veklury (Remdesivir) to Patients..
AQ
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 25 204 M - -
Net income 2022 3 837 M - -
Net Debt 2022 16 272 M - -
P/E ratio 2022 20,4x
Yield 2022 4,56%
Capitalization 80 128 M 80 128 M -
EV / Sales 2022 3,82x
EV / Sales 2023 3,80x
Nbr of Employees 14 400
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 63,93 $
Average target price 71,20 $
Spread / Average Target 11,4%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Kevin E. Lofton Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-11.95%78 498
REGENERON PHARMACEUTICALS, INC.10.05%74 302
VERTEX PHARMACEUTICALS29.66%73 024
BIONTECH SE-49.46%31 665
WUXI APPTEC CO., LTD.-40.29%29 141
GENMAB A/S-5.82%20 858